





Pediatric Rheumatology Studies Open for Enrollment

Study	Disease	Overview	Eligibility
CARRA Registry 	JIA SLE JDM	Registry to monitor clinical course and long-term safety of medications. Participants complete questionnaires 2x a year at SOC visits for 10 years.	JIA <ul style="list-style-type: none"> • Younger than age 16 y.o. • DX w/in 6 months SLE <ul style="list-style-type: none"> • Onset prior to age 18 y.o. • DX w/in 2 years or new nephritis JDM <ul style="list-style-type: none"> • Onset prior to age 19 y.o. • DX w/in 6 months
CARRA Sub Studies			
CARRA Biorepository	SLE JDM	<ul style="list-style-type: none"> • Collect blood samples at baseline SLE or JDM visit • CLUE – all SLE patients eligible for 1 time sample collection 	
PROMOTE 	JIA	Predicting response to MTX. Data collected at 0, 3, and 6 months. Bioample collected at 6 months.	<ul style="list-style-type: none"> • All JIA starting MTX without biologic • No systemic JIA
PRECISE PREC ision biologics rheumatology *separate IRB	JIA	Observational study evaluating effect of obesity on PK/PD of biologics in JIA. Several blood samples collected. *Participants receive \$35 per visit	<ul style="list-style-type: none"> • >2 y.o. • Oligo, poly, psoriatic, ERA • Start etanercept or adalimumab • BMI≥85%
LIMIT JIA  *separate IRB	JIA	Trial evaluating efficacy of abatacept in preventing extension of limited JIA. Study lasts 18 months with visits every 3 months. *no placebo, free abatacept *Participants receive \$25 per visit	<ul style="list-style-type: none"> • 2-16.5 y.o. • DX of limited JIA (≤4 joints) in 6 mo • No uveitis, psoriasis, sacroillitis, IBD • DMARD and biologic naïve
Other Studies			
PSUMMIT-Jr 	Psoriatic JIA	PK and efficacy of Stelara and Tremfya in jPsA *no placebo, free medication *participants receive \$75 per visit	<ul style="list-style-type: none"> • 5-18 y.o. with active jPsA • ≥3 joints with arthritis
Psychological Stress and Cardiovascular Health in Juvenile Lupus and DM	SLE JDM	Assess psychological stress and CV health indicators in jSLE and JDM at SOC visits x 12 months *Lipids & HbA1c at 0, 6, 12 months *Research samples at 0, 12 months	<ul style="list-style-type: none"> • 5 to 22 y.o. with SLE & JDM • Any time in disease course
CHOIR Registry CH ronic nonbacterial O steomyelitis I nternational R egistry	CNO	Data registry to investigate the natural history and management of CRMO. Participants complete questionnaires at every SOC visit for 5 years.	<ul style="list-style-type: none"> • <21 y.o. with CNO

COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders	SLE JIA JDM	Evaluate COVID IgG response after additional vaccine dose Randomized to take Rx as is or altered around time of booster	<ul style="list-style-type: none"> • 5-17 y.o. with SLE, JIA, JDM, or MS • On MTX, MMF/MPA, and/or B cell depleting therapy within 18 months • COVID vaccine within 52 weeks • Poor COVID IgG response
PLUMM	SLE with LN	Compare efficacy of MMF _{PK} to MMF _{BSA} as measured by partial and complete remission in proliferative lupus nephritis	<ul style="list-style-type: none"> • 8-17 y.o. with SLE and proliferative LN diagnosed by BX within 30 days
Tofacitinib in sJIA	sJIA	Evaluate efficacy of tofa in sJIA as measured by time-to-flare in double-blind, randomized withdrawal phase	<ul style="list-style-type: none"> • 2-17 y.o. with sJIA • Fever and ≥ 2 joints with arthritis
Pulmonary Capillaritis Registry	IPC	Data registry to investigate the natural history and management of IPC.	<ul style="list-style-type: none"> • <21 y.o. with biopsy-proven IPC